Home Latest news Treatment of congenital muscular dystrophy with merosin (laminin alpha 2) deficiency

Treatment of congenital muscular dystrophy with merosin (laminin alpha 2) deficiency

by admin
549 views

On 8/05/2008, a new orphan medicinal product was registered into the community register of orphan medicinal products under the EU orphan designation number 544. The active ingredient is Omigapil maleate for treatment of congenital muscular dystrophy with merosin (laminin alpha 2) deficiency.

Related Articles